This vaccine enriches in lymph nodes, promotes DC-mediated antigen cross-presentation, and activates tumor-specific cytotoxic T lymphocytes (CTLs); In B16F10 murine models, C/G-HL-Man combined with fenofibrate and PD-1 antibodies suppressed recurrent melanoma progression and extended survival (82). This evidence concerns the gene PDCD1 and neoplasm.